Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics.

MLA

Hansen, B. E., et al. “Maralixibat-Treated Patients with Alagille Syndrome (ALGS) Demonstrate Improved Event-Free Survival in a Natural History Comparison with Patients from the GALA Database: Application of Real-World Evidence Analytics.” Journal of Pediatric Gastroenterology & Nutrition, vol. 74, June 2022, pp. 670–73. EBSCOhost, https://doi.org/10.1097/MPG.0000000000003446.

APA

Hansen, B. E., Vandriel, S. M., Vig, P., Garner, W., Li, L.-T., She, H., Wang, J.-S., Gilbert, M. A., Jankowska, I., Czubkowski, P., Gliwicz-Miedzińska, D., Gonzales, E. M., Jacquemin, E., Bouligand, J., Spinner, N. B., Loomes, K. M., Piccoli, D. A., D’Antiga, L., Nicastro, E., & Sokal, É. (2022). Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics. Journal of Pediatric Gastroenterology & Nutrition, 74, 670–673. https://doi.org/10.1097/MPG.0000000000003446

Chicago

Hansen, B. E., S. M. Vandriel, P. Vig, W. Garner, L.-T. Li, H. She, J.-S. Wang, et al. 2022. “Maralixibat-Treated Patients with Alagille Syndrome (ALGS) Demonstrate Improved Event-Free Survival in a Natural History Comparison with Patients from the GALA Database: Application of Real-World Evidence Analytics.” Journal of Pediatric Gastroenterology & Nutrition 74 (June): 670–73. doi:10.1097/MPG.0000000000003446.